Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer

Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer

Background: Pembrolizumab monotherapy for non-small-cell lung cancer (NSCLC) expressing PD-L1 ≥ 50% doubles five-year survival rates compared to chemotherapy. However, immune-related adverse events (irAEs) can cause severe, long-term toxicity necessitating high-dose steroids and/or treatment cessati...

Full description

Bibliographic Details
Main Authors: George Raynes, Mark Stares, Samantha Low, Dhania Haron, Hussain Sarwar, Dhruv Abhi, Colin Barrie, Barry Laird, Caledonian Cachexia Collaborative, Iain Phillips, Melanie MacKean
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Cancers
Subjects:
biomarkers of systemic inflammation
Scottish Inflammatory Prognostic Score (SIPS)
non-small-cell lung cancer
immune-related adverse events
pembrolizumab
Online Access:https://www.mdpi.com/2072-6694/15/23/5502

Internet

https://www.mdpi.com/2072-6694/15/23/5502

Similar Items